Literature DB >> 15454728

Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.

Carmela Gnerre1, Sharon Blättler, Michel R Kaufmann, Renate Looser, Urs A Meyer.   

Abstract

CYP3A4, the most abundant cytochrome P450 in human liver, is responsible for the metabolism of numerous xenobiotics and endobiotics. CYP3A4 expression is highly variable and is induced by numerous compounds of exogenous and endogenous origin, including elevated concentrations of secondary bile acids via the pregnane X receptor (PXR). We show that physiological concentrations of the primary bile acid chenodeoxycholic acid regulate the expression of CYP3A4 via the bile acid receptor FXR. Experiments performed in vitro in different cell culture systems, gel-mobility shift assays and experiments performed in vivo in transgenic mice lacking FXR or PXR and treated with the synthetic FXR agonist GW4064 were undertaken to study the implication of FXR in the regulation of CYP3A. Our data provide evidence for the presence of two functional FXR recognition sites located in a 345-bp element within the 5'-flanking region of CYP3A4. Mutational analysis of these sites and experiments in transgenic mice lacking FXR or PXR support the relevance of FXR activation for CYP3A regulation. Thus, whereas elevated concentrations of precursors of bile acids and secondary bile acids induce CYP3A via PXR, primary bile acids can modulate the expression of CYP3A via FXR. These findings may explain elevated CYP3A expression in cholestasis and part of the variability of drug responsiveness and toxicity between individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454728     DOI: 10.1097/00008571-200410000-00001

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  38 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

3.  Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters.

Authors:  Christophe Gardès; Evelyne Chaput; Andreas Staempfli; Denise Blum; Hans Richter; G Martin Benson
Journal:  J Lipid Res       Date:  2013-02-21       Impact factor: 5.922

4.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity.

Authors:  Florence Ying Lee; Thomas Quad de Aguiar Vallim; Hansook Kim Chong; Yanqiao Zhang; Yaping Liu; Stacey A Jones; Timothy F Osborne; Peter A Edwards
Journal:  Mol Endocrinol       Date:  2010-06-23

Review 5.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

6.  Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s.

Authors:  Amarjit S Chaudhry; Ranjit K Thirumaran; Kazuto Yasuda; Xia Yang; Yiping Fan; Stephen C Strom; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2013-05-23       Impact factor: 3.922

Review 7.  Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective.

Authors:  Bret D Wallace; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2012-12-05       Impact factor: 4.518

8.  Regulation of human class I alcohol dehydrogenases by bile acids.

Authors:  Cédric Langhi; Elena Pedraz-Cuesta; Diego Haro; Pedro F Marrero; Joan C Rodríguez
Journal:  J Lipid Res       Date:  2013-06-16       Impact factor: 5.922

9.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

10.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.